Statistical considerations for the next generation of clinical trials

Wenting Wu, Qian D Shi, Daniel J. Sargent

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

In this article, we address some of the statistical issues associated with the next generation of oncology clinical trials. Specifically, we focus on two critical aspects of oncologic clinical trials: study endpoints and study design. In our discussion of study endpoints, we provide an overview of endpoints relevant to each phase of clinical trials (phases I, II, and III) and discuss some of the trends in selecting endpoints in recent years. For phase I designs, the traditional assumption that increasing dose will always lead to increasing efficacy, appropriate for cytotoxic agents, is not applicable to novel therapeutics such as in colorectal carcinoma. We emphasize the role of surrogate endpoints in modern clinical trials. In our discussion of study design, we are particularly interested in the essential role of randomization, and discuss recently developed randomized phase II designs. We consider the role biomarkers play in the design of clinical trials and introduce study designs for biomarker evaluations. Finally, we briefly discuss the application of adaptive designs in clinical trials.

Original languageEnglish (US)
Pages (from-to)598-604
Number of pages7
JournalSeminars in Oncology
Volume38
Issue number4
DOIs
StatePublished - Aug 2011

Fingerprint

Clinical Trials
Biomarkers
Phase III Clinical Trials
Phase II Clinical Trials
Clinical Trials, Phase I
Cytotoxins
Random Allocation
Colorectal Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Statistical considerations for the next generation of clinical trials. / Wu, Wenting; Shi, Qian D; Sargent, Daniel J.

In: Seminars in Oncology, Vol. 38, No. 4, 08.2011, p. 598-604.

Research output: Contribution to journalArticle

Wu, Wenting ; Shi, Qian D ; Sargent, Daniel J. / Statistical considerations for the next generation of clinical trials. In: Seminars in Oncology. 2011 ; Vol. 38, No. 4. pp. 598-604.
@article{ae0691ac24194cdeb6e54e28b03adc93,
title = "Statistical considerations for the next generation of clinical trials",
abstract = "In this article, we address some of the statistical issues associated with the next generation of oncology clinical trials. Specifically, we focus on two critical aspects of oncologic clinical trials: study endpoints and study design. In our discussion of study endpoints, we provide an overview of endpoints relevant to each phase of clinical trials (phases I, II, and III) and discuss some of the trends in selecting endpoints in recent years. For phase I designs, the traditional assumption that increasing dose will always lead to increasing efficacy, appropriate for cytotoxic agents, is not applicable to novel therapeutics such as in colorectal carcinoma. We emphasize the role of surrogate endpoints in modern clinical trials. In our discussion of study design, we are particularly interested in the essential role of randomization, and discuss recently developed randomized phase II designs. We consider the role biomarkers play in the design of clinical trials and introduce study designs for biomarker evaluations. Finally, we briefly discuss the application of adaptive designs in clinical trials.",
author = "Wenting Wu and Shi, {Qian D} and Sargent, {Daniel J.}",
year = "2011",
month = "8",
doi = "10.1053/j.seminoncol.2011.05.014",
language = "English (US)",
volume = "38",
pages = "598--604",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Statistical considerations for the next generation of clinical trials

AU - Wu, Wenting

AU - Shi, Qian D

AU - Sargent, Daniel J.

PY - 2011/8

Y1 - 2011/8

N2 - In this article, we address some of the statistical issues associated with the next generation of oncology clinical trials. Specifically, we focus on two critical aspects of oncologic clinical trials: study endpoints and study design. In our discussion of study endpoints, we provide an overview of endpoints relevant to each phase of clinical trials (phases I, II, and III) and discuss some of the trends in selecting endpoints in recent years. For phase I designs, the traditional assumption that increasing dose will always lead to increasing efficacy, appropriate for cytotoxic agents, is not applicable to novel therapeutics such as in colorectal carcinoma. We emphasize the role of surrogate endpoints in modern clinical trials. In our discussion of study design, we are particularly interested in the essential role of randomization, and discuss recently developed randomized phase II designs. We consider the role biomarkers play in the design of clinical trials and introduce study designs for biomarker evaluations. Finally, we briefly discuss the application of adaptive designs in clinical trials.

AB - In this article, we address some of the statistical issues associated with the next generation of oncology clinical trials. Specifically, we focus on two critical aspects of oncologic clinical trials: study endpoints and study design. In our discussion of study endpoints, we provide an overview of endpoints relevant to each phase of clinical trials (phases I, II, and III) and discuss some of the trends in selecting endpoints in recent years. For phase I designs, the traditional assumption that increasing dose will always lead to increasing efficacy, appropriate for cytotoxic agents, is not applicable to novel therapeutics such as in colorectal carcinoma. We emphasize the role of surrogate endpoints in modern clinical trials. In our discussion of study design, we are particularly interested in the essential role of randomization, and discuss recently developed randomized phase II designs. We consider the role biomarkers play in the design of clinical trials and introduce study designs for biomarker evaluations. Finally, we briefly discuss the application of adaptive designs in clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=79961006796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961006796&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2011.05.014

DO - 10.1053/j.seminoncol.2011.05.014

M3 - Article

VL - 38

SP - 598

EP - 604

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 4

ER -